Cristina Christopher
Internal Medicine · Glendora, CANPI 1235378613
Payments from drug & device makers
Across 288 payments — averaging $17.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$790
- Amgen$688
- Lilly USA, LLC$678
- Novo Nordisk$602
- AstraZeneca$298
- Boehringer Ingelheim$284
- plus $2K from 28 others
What the payments were for
- Food & beverage$5,025100%
- Education$250%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 52 | $790 |
| Amgen(2 entities) | 40 | $688 |
| Lilly USA, LLC | 39 | $678 |
| Novo Nordisk | 38 | $602 |
| AstraZeneca | 13 | $298 |
| Boehringer Ingelheim | 18 | $284 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $266 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 17 | $239 |
| Pfizer | 11 | $207 |
| Bayer | 4 | $99 |
| GSK | 5 | $96 |
| Exact Sciences | 4 | $75 |
| Antares Pharma, Inc. | 4 | $71 |
| Kowa Pharmaceuticals America, Inc. | 3 | $65 |
| Almatica Pharma LLC | 3 | $61 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $57 |
| Regeneron Healthcare Solutions, Inc. | 2 | $48 |
| Biohaven Pharmaceuticals, Inc. | 2 | $46 |
| Johnson & Johnson | 2 | $41 |
| Teva Pharmaceuticals USA, Inc. | 1 | $41 |
| Currax Pharmaceuticals LLC | 2 | $39 |
| Eisai Inc. | 2 | $38 |
| Sanofi Pasteur Inc. | 2 | $36 |
| Novartis | 1 | $24 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| Dexcom, Inc. | 1 | $21 |
| IBSA Pharma Inc. | 1 | $19 |
| Ironwood Pharmaceuticals, Inc | 1 | $18 |
| Corcept Therapeutics | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Astellas Pharma US Inc | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $11 |
How this compares
$5,050 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 27 | $26,501 |
| MounjaroTirzepatide | 21 | $20,704 |
| XareltoRivaroxaban | 11 | $6,345 |
| Almotriptan Malate | 18 | $1,614 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $1,540 |
| Levothyroxine Sodium | 65 | $1,058 |
| Potassium Chloride | 17 | $829 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 15 | $794 |
| Duloxetine Hcl | 32 | $692 |
| Armodafinil | 11 | $652 |
| Losartan Potassium | 51 | $543 |
| Pantoprazole Sodium | 44 | $503 |
| Pregabalin | 21 | $486 |
| Atorvastatin Calcium | 45 | $486 |
| Tramadol Hcl | 79 | $473 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $602 | $26,50127 claims |
| Lilly USA, LLCMounjaro | $678 | $20,70421 claims |
| Johnson & JohnsonXarelto | $41 | $6,34511 claims |
| Almatica Pharma LLCSertraline Hcl | $61 | $19029 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Glendora
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- Donald BrandonSan Diego$34M
- William TownerLos Angeles$27.4M
- Rahul AggarwalSan Francisco$24M
- Masoud AzizadNorthridge$21.1M
- Helen StaceyWalnut Creek$20.4M
- Rohit Loombala Jolla$15.1M
- Zeid KayaliColton$14.2M
- Alexandra DrakakiSanta Monica$14.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.